Rosetta Genomics introduces new cancer test

Posted on: Tue, 30 Dec 2008 06:49:00 EST


Symbols: ROSG
Dec 30, 2008 (Datamonitor via COMTEX) --
ROSG | Quote | Chart | News | PowerRating -- Rosetta Genomics, a developer of microRNA-based molecular diagnostics, has introduced its third diagnostic test, miRview meso.

The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

miRview meso differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung, the company said.

Rosetta Genomics expects to perform approximately 2,000 tests during 2009 in its laboratory in Philadelphia, Pennsylvania.

Harvey Pass, division chief of thoracic surgery and thoracic oncology at the New York University Langone Medical Center, said: "I am very excited to finally see a molecularly based test that can objectively differentiate mesothelioma from several types of carcinomas in the lung with such high level of accuracy. Ruling out mesothelioma from lung cancer for individuals that were exposed to asbestos can be difficult and challenging. I am sure that this test will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

For full details on Rosetta Genomics Ltd Ord (ROSG) ROSG. Rosetta Genomics Ltd Ord (ROSG) has Short Term PowerRatings at TradingMarkets. Details on Rosetta Genomics Ltd Ord (ROSG) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.